Effective and Safe Treatment of Psoriatic Disease with the Anti-IL-23p19 Biologic Tildrakizumab: Results of a Real-World Prospective Cohort Study in Nonselected Patients

BACKGROUND: After registration of drugs, evidence about efficacy and safety is solely based on data of phase 2/3 clinical trial programs. A major drawback is the selection of patients following inclusion/exclusion criteria. There is a considerable time and knowledge gap between study and registry da...

Descripción completa

Detalles Bibliográficos
Autores principales: Drerup, Katharina A., Seemann, Claudia, Gerdes, Sascha, Mrowietz, Ulrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393809/
https://www.ncbi.nlm.nih.gov/pubmed/34775387
http://dx.doi.org/10.1159/000519924

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393809/
https://www.ncbi.nlm.nih.gov/pubmed/34775387
http://dx.doi.org/10.1159/000519924

Ejemplares similares